Created at	Source	Raw Value	Validated value
Oct. 26, 2020, 8:29 a.m.	oms	1. Safety and adverse events measured using i.v. administration of 0.2mg/kg of placental; mesenchymal stem cell-derived exosome preparations (KTA 100;= XoGlo®) at day 1 and day 3 2. Improved respiration measured using PaO2/FiO2 at day 1; 2; and onwards daily	1. Safety and adverse events measured using i.v. administration of 0.2mg/kg of placental; mesenchymal stem cell-derived exosome preparations (KTA 100;= XoGlo®) at day 1 and day 3 2. Improved respiration measured using PaO2/FiO2 at day 1; 2; and onwards daily